Signal Transduction Inhibitors
Peroxiredoxins in the lung with emphasis on peroxiredoxin VI
Sub-cellular Biochemistry. 2007;44:317-44. [Link] Schremmer B, Manevich Y, Feinstein SI, Fisher AB. Institute for Environmental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Abstract All six mammalian peroxiredoxins are expressed in the lung. Peroxiredoxin (Prx) VI is the isoform expressed at the highest level and its lung expression exceeds that for other organs. The predominant…
Read MoreFunctional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma
Cancer Research. 66, 352-361, January 1, 2006]. [Link] Ramasamy Jagadeeswaran1, Patrick C. Ma1, Tanguy Y. Seiwert1, Sujatha Jagadeeswaran1, Osvaldo Zumba1, Vidya Nallasura1, Salman Ahmed1, Rosangela Filiberti2, Michela Paganuzzi2, Riccardo Puntoni2, Robert A. Kratzke3, Gavin J. Gordon4, David J. Sugarbaker4, Raphael Bueno4, Varalakshmi Janamanchi1, Vytas P. Bindokas1, Hedy L. Kindler1 and Ravi Salgia1 1 Section of…
Read MoreCox and mesothelioma: an overview
Histology and Histopathology. 2005 Oct;20(4):1267-74. [Link] Cardillo I, Spugnini EP, Verdina A, Galati R, Citro G, Baldi A. SAFU Department, Center for Experimental Research, Regina Elena Cancer Institute, Rome, Italy. Abstract Cyclooxygenases catalyze the rate limiting step in the production of prostanoids. Accumulating data demonstrate that overexpression of these enzymes, and in particular of cyclooxygenases-2,…
Read MoreHuman and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth
Oncogene. 2005 Sep 8;24(40):6080-9. [Link] Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB, Testa JR. Human Genetics Program, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA Abstract Malignant mesotheliomas (MMs) are very aggressive tumors that respond poorly to standard chemotherapeutic approaches.…
Read MoreReceptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma
The Journal of Thoracic and Cardiovascular Surgery 2005 Aug;130 (2):393-400 Philip A. Rascoe, MDa, Xiaobo Cao, MDb, Jonathan C. Daniel, MDa, Steven D. Miller, MDa, W. Roy Smythe, MDb,* a Department of Thoracic and Cardiovascular Surgery, Section of Thoracic Molecular Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Tex b Scott and White…
Read MoreTherapeutic Targeting of Multiple Signaling Pathways in Malignant Pleural Mesothelioma
Oncology. July 13, 2005;68:500-510. [Link] Toru Mukoharaa-c, Gabriel Civielloa, Bruce E. Johnsona-c, Pasi A. Jännea-c aLowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute; Departments of Medicine, bBrigham and Women’s Hospital and cHarvard Medical School, Boston, Mass., USA Abstract The majority of malignant pleural mesotheliomas (MPMs) aberrantly express the epidermal growth factor…
Read More